Remdesibir maker “moves fast with FDA”

Remdesibir from Gilead Science. © Reuters = News 1

Gilead Sciences said it is working with the United States Food and Drug Administration (FDA) to quickly approve the antiviral drug ‘Remedyvir’ for use in Corona 19.

Daniel O’Day Gilliard, CEO, appeared on NBC on 1 and said he wants the FDA to expedite approval for emergency use.

“We are focusing on making Remdesivir easy and affordable for patients around the world,” said the CEO of Oday.

Gilead plans to increase Remdesibir production in 10 days in December to 1 million, and plans to have more production capacity next year.

Gilead announced that in a trial of 397 critically ill patients, Remdesivir was shown to help improve symptoms of the Corona infection19.

Gilead explained that Remdesivir was more effective in patients with a crown19 who were administered earlier than those who were subsequently dosed.

Gilead suggested that 62% of patients who were treated early were discharged, and 49% of patients who were treated late were discharged.

[email protected]